



Skyrizi in Qatar

The MOPH named-patient coordination pathway — indicative 2026

IMMUNOLOGY · IL-23 P19

The clinical situation

Skyrizi (risankizumab) is an FDA-approved humanised monoclonal antibody to the p19 subunit of IL-23 indicated for moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn disease, and ulcerative colitis. Manufactured by AbbVie. Dosing is 150 mg SC at weeks 0 and 4 then every 12 weeks for psoriasis/PsA, with indication-specific IV induction for IBD; refrigerated storage 2-8°C, patient- or provider-administered pen or syringe.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating dermatologist, rheumatologist, or gastroenterologist documents diagnosis severity, TB/HBV/HCV screening, and prior biologic history.
- 2 Treating centre confirmed.** A Qatari tertiary centre in Doha or affiliated HMC facility accepts the case.
- 3 MOPH named-patient application.** Clinical rationale, patient reference, product details, and cold-chain plan are filed with the MOPH pharmacy & drug control department.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner; temperature-monitored 2-8°C shipment.
- 5 Arrival & administration.** Patient self-administers SC at home after nurse training (IV induction centre-based for IBD); response reassessed at 16 weeks.

Indicative economics

Reference US cash-pay range: USD 18,000–20,000 per quarterly dose. MOPH documentation, cold-chain logistics, and concierge coordination are incremental. Full transparent quote at intake.

Indicative first-dose timing

7–14 days from a complete MOPH application to first-dose delivery, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and MOPH review. **Logistics.** Temperature-monitored cold-chain shipment coordination. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating specialist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Skyrizi × Qatar first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/skyrizi-qatar.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team